Repligen (RGEN) Has Rejected an Initial Takeover Offer from Catalent (CTLT) - Source
Tweet Send to a Friend
Repligen (Nasdaq: RGEN), a bioprocessing company with a market capitalization of about $14 billion, hired advisers for takeover defense after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE